This site is intended for healthcare professionals
Secukinumab gets EC approval for treating hidradenitis suppurativa
Cosentyx® (secukinumab) became the only new biologic approved in the last decade for this condition. It provided rapid symptom relief by week 4, with increasing response rates for up to a year. The safety profile of the drug was already established across other indications. The drug is also used fot treating plaque psoriasis, spondylitis, spondyloarthritis, and arthritis.
First topical gene therapy gets FDA approval
Vyjuvek is a herpes simplex virus type 1 vector-based therapy that can be used for treating wounds in individuals aged 6 months and older suffering from dystrophic epidermolysis bullosa with COL7A1 gene mutations. It improved wound healing from this skin condition with 100% wound closure in 24 weeks. Itching, redness, chills and cough were commonly seen adverse reactions.
CDC reports drug-resistant ringworm cases
The two cases reported in two unrelated people are the first ever cases recorded in the US. The patients had severe cases of topical tinea that did not resolve with initial treatment. However, the agency said there was not much threat to public health. Trichophyton indotineae, a ringworm-causing, highly transmissible, resistant fungus, caused these infections.
FDA places hold on a trial on alopecia drug
Deuruxolitinib, a selective oral JAK1 and JAK2 inhibitor, caused pulmonary embolism at 12 mg twice daily dose in study participants. As a result, the agency placed a partial hold and suggested participants take this dose to discontinue the drug. On the other hand, no thrombotic events were seen with an 8 mg twice daily dose. The drug received Breakthrough Therapy designation.
Supplements may contain hidden allergens
Hidden allergens in supplements can range from coloring agents to vitamins in hair products, as per a study. Dermatologists also say that patients do not discuss the dietary supplements they consume, making it challenging to identify potential allergens. Red pigment carmine from beetles, gelatin, certain vitamins, some herbs and spices are some of the culprits.
US Today News
FDA approves a new treatment to correct cheek wrinkles
Sculptra® (injectable poly-L-lactic acid (PLLA-SCA)) is an original and the first PPLA collagen stimulator approved for the correction of wrinkles and fine lines in the full cheek area. It can be used in patients with healthy immune systems. People on therapy had sustained aesthetic improvements, where 94% showed improvements in wrinkles and skin glow even at two years.
Squamous cell carcinoma after breast implants is rare
The incidence of SCC in women after breast reconstruction from implants was very low, as per analysis. Only a few cases have been identified after long latency periods after the procedure. But an increased incidence of breast implant-associated anaplastic large-cell lymphoma was observed. Women should be counselled about these risks but not discouraged from getting implants.
EU approves ruxolitinib cream to treat vitiligo
Opzelura® (ruxolitinib) Cream became the only approved treatment for treating individuals aged 12 years and above with non-segmental vitiligo with facial involvement. The selective JAK1/JAK2 inhibitor caused improvements in the repigmentation of the face and total body compared to a vehicle in phase 3 trials. Application site acne was the most common side effect.
USPSTF issues updated screening guidelines for skin cancer
They suggest there was no evidence to advise for or against screening people without symptoms using visual skin exams. It does not apply to people at a higher risk of skin cancer. Clinicians are asked to use the ABCDE rule while looking at skin lesions. Treatment options include surgical removal of the primary tumor and immuno- or targeted therapies for advanced melanoma.
US Preventive Services Task Force
FDA approves the first sweat control patch for axillary hyperhidrosis
Brella™ is a 3-Minute SweatControl Patch that adults can wear underarms to control excessive underarm sweat due to primary axillary sweating. It is a fast, need-free, non-invasive, affordable, and aluminium-free treatment option, producing results that last 3 to 4 months, as per studies. The patch improved the quality of life without causing severe adverse events.